Guides for diagnostic development
Getting paid takes three separate wins: a billing code, a coverage decision and a payment rate. FDA clearance and a CLIA license make a test legal to offer, but guarantee none of the three. Plan reimbursement in parallel with development, because payers judge the evidence you generate.
The three wins
Step 1
A billing code that identifies your test on a claim.
Step 2
A payer's decision that the test is medically necessary for certain patients.
Step 3
The amount the payer pays per test, set for Medicare through the Clinical Laboratory Fee Schedule.
1. Coding
2. Coverage
3. Payment
Medicare pays lab tests from the Clinical Laboratory Fee Schedule. For a new code, CMS holds an annual public meeting where labs present data on what the test should be paid. An advisory panel then recommends a crosswalk, pricing the test like a similar existing one, or gapfill, where contractors set local prices that CMS turns into a national median when no comparable test exists. CMS posts preliminary decisions in September and finalizes them in November, with a 60-day window for reconsideration. Gapfill takes roughly nine months longer but can better reflect the cost of a truly novel test.
Advanced Diagnostic Laboratory Tests (ADLTs) are a special category for single-lab tests that combine multiple DNA, RNA or protein biomarkers with a unique algorithm, or that are FDA-cleared or approved. ADLT status brings a different payment basis, starting with the lab's list price for an initial period.
PAMA and 2027 rates. Fee schedule rates follow what private payers paid. Labs reported 2025 private-payer data in 2026; new rates take effect January 1, 2027, with cuts of up to 15% a year possible through 2029. As of November 2026 the RESULTS Act, which would freeze rates and limit future cuts, had not passed. Check the current rate before building a business case.
Evidence
Does the test measure accurately?
Your CLIA or FDA validation: accuracy, precision and detection limits.
Does the result track the condition?
Clinical studies reporting sensitivity, specificity, predictive values or risk.
Does using it improve care?
Studies showing changed decisions, better outcomes or savings; guideline inclusion; health-economic models.
Clinical utility is usually the hardest to show. Publish in peer-reviewed journals, since most technical assessments and medical policies only weigh published data, and design studies in the population the payer covers.
Roadmap
Sources: AMA, CPT PLA codes · Noridian, MolDX · CMS, CLFS annual public meetings · ADLM, PAMA reform (Aug 2026) · ADS, lab reimbursement review (Nov 2026)
We develop and validate tests, run them in our CLIA/CAP laboratory, and support the evidence and submissions payers need.